| Identification | Back Directory | [Name]
SR 11237 | [CAS]
146670-40-8 | [Synonyms]
BMS649
SR 11237
BMS 188649
4-[2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl]-benzoicacid
4-(2-(5,5,8,8-tetraMethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-1,3-dioxolan-2-yl)benzoic acid
Benzoic acid, 4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl]- | [Molecular Formula]
C24H28O4 | [MDL Number]
MFCD00864137 | [MOL File]
146670-40-8.mol | [Molecular Weight]
380.48 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: >28mg/mL (warmed) | [form ]
powder | [color ]
white to off-white | [InChI]
1S/C24H28O4/c1-22(2)11-12-23(3,4)20-15-18(9-10-19(20)22)24(27-13-14-28-24)17-7-5-16(6-8-17)21(25)26/h5-10,15H,11-14H2,1-4H3,(H,25,26) | [InChIKey]
ZZUKALQMHNSWTK-UHFFFAOYSA-N | [SMILES]
CC1(C)CCC(C)(C)c2cc(ccc12)C3(OCCO3)c4ccc(cc4)C(O)=O |
| Hazard Information | Back Directory | [Uses]
SR 11237 is a pan RXR agonist with without RAR activity. It is used in treatment of neurodegenerative diseases. | [Biological Activity]
Pan retinoid X receptor (RXR) agonist that is devoid of any RAR activity. | [in vivo]
SR11237 (BMS-649) (25 mg/kg; i.p.; daily from post-natal days 5 to 15) causes irregular ossification and premature closure of the growth plate[2]. | Animal Model: | Sprague-Dawley rats[2] | | Dosage: | 25 mg/kg | | Administration: | I.p.; daily from post-natal days 5 to 15 | | Result: | Caused disturbed ossification and bone morphology in rats, including premature growth plate closure and infiltration of ossified tissue through the central epiphysis.
|
| [storage]
Store at -20°C |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
|